STK17A antibody (N-Term)
Quick Overview for STK17A antibody (N-Term) (ABIN359415)
Target
See all STK17A AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Specificity
- This antibody detects DRAK1 at N-term.
-
Purification
- Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human DRAK1.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
ELISA 1: 1,000. Western blot 1: 100 - 1: 500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody at 2 - 8 °C up to one month or (in aliquots) at -20 °C for longer.
-
-
- STK17A (serine/threonine Kinase 17a (STK17A))
-
Alternative Name
- STK17A / DRAK1
-
Background
- DRAK1 is a member of the DAP kinase-related apoptosis-inducing protein kinase family and encodes an autophosphorylated nuclear protein with a protein kinase domain. The protein has apoptosis-inducing activity.Synonyms: DAP kinase-related apoptosis-inducing protein kinase 1, Serine/threonine-protein kinase 17A
-
Molecular Weight
- 46559 Da
-
Gene ID
- 9263, 9606
-
UniProt
- Q9UEE5
Target
-